Lennart Bunch
Professor
Medicinal Chemistry
Jagtvej 162
2100 København Ø
Ever since my first experience with organic chemistry as an undergraduate, I have been spellbound with this field of research: The ability of mankind to synthesize any compound of interest and hereafter investigate how a structural change affects its biological activity. The intellectual aspect of rational drug design and synthesis is to me captivating and motivates me every day I go to work.
My passion for natural science made it easy for me to choose my undergraduate studies as a chemical engineer with special focus on organic synthesis and quantum chemistry. My eager to learn more and understand the fundamentals of organic chemistry drove me to pursue a 2-year master study at Florida State University (FSU) in the USA. Accepting an offer of full tuition-waiver and a teaching position at FSU, those two years of intensive study made it clear to me that I wanted to establish a research group in academia within the field of organic and medicinal chemistry.
Returning to my home country for a PhD study in organic chemistry/medicinal chemistry was an easy choice for me. The topic of my thesis was new ligands for the glutamat receptors - a fascinating field within CNS research! Changing my focus for a while, I chose to do my postdoc at DTU in Denmark within organometallic chemistry developing new methodology.
My determinacy to pursue an academic career prompted me to apply for a three-year Assistant Professorship through the Danish Research Foundation, and was granted this in 2003 within the field of glutamatergic neurotransmission.
In 2006, I was promoted to Associate Professor and began to build-up my own research group – the Bunch Research Group
SCIENTIFIC KEY QUALIFICATIONS
- Organic Chemistry: new methodology relevant for medicinal chemistry
- Medicinal Chemistry: small molecule design, structure-based design, new techniques
- Computational chemistry: docking, binding modes,
- Developement of tool compounds for the study of health and disease in the CNS
ID: 1302517
Most downloads
-
267
downloads
The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
177
downloads
Chemoenzymatic synthesis and pharmacological characterization of functionalized aspartate analogues as novel excitatory amino acid transporter inhibitors
Research output: Contribution to journal › Journal article › Research › peer-review
Published